Advances in Urologic Imaging Prostate-Specific Membrane Antigen Ligand PET Imaging

Radiolabeled prostate-specific membrane antigen (PSMA) PET is emerging as an important modality for imaging prostate cancer (PCa). Promising clinical experience has led to increasing number of studies exploring the role of PSMA PET in different aspects of PCa, including primary detection, risk stratification, targeted biopsy, initial staging, restaging at biochemical recurrence, biologic characterization, treatment response assessment, and prognostication. PSMA PET may prove an important disease biomarker, expand our understanding of the pathogenesis, and pave the way for personalized management of PCa.